Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 100-106

  Wolski, Michal J ^a   Bhatnagar, Ajay ^a   Flickinger, John C ^a   Belani, Chandra P ^a   Ramalingam, Suresh ^a   Greenberger, Joel S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Esophagitis; Paclitaxel; Pneumonitis

Indexed keywords

CARBOPLATIN; PACLITAXEL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS DISEASE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT CARE; RADIATION DOSE; SURVIVAL RATE;

EID: 31944452746     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.024     Document Type: Article

References (63)

1. Cox JD, Le Chevalier T, Arriagada R, et al. Management of unresectable non-small cell carcinoma of the lung (NSCLC). Lung Cancer 2003; 42:S15-S16.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392.
3. Bahri S, Flickinger JC, Kalend AM, et al. Results of multifield conformal radiation therapy of non-small-cell lung carcinoma using multileaf collimation beams. Radiat Oncol Investig 1999; 7:297-308.
4. Bhatnagar A, Flickinger JC, Bahri S, et al. Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams. Clin Lung Cancer 2002; 3:259-264.
5. RTOG toxicity scoring criteria. Available at: http://www.rtog.org/members/main.html. Accessed July 15, 2004.
6. Armstrong JG, Burman C, Leibel S, et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 1993; 26:685-689.
7. Graham MV, Jaiu NL, Kahn MG, et al. Evaluation of objective plan-evaluation model in the three-dimensional treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 34:469-474.
8. Graham MV, Matthews JW, Harms WB Sr, et al. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys 1994; 29:1105-1117.
9. Boxwala AA, Rosenman JG. Retrospective reconstruction of three-dimensional radiotherapy treatment plans of the thorax from two dimensional planning data. Int J Radiat Oncol Biol Phys 1994; 28:1009-1015.
10. Manel MK, Ten Haken RK, Hazuka MB, et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994; 28:575-581.
11. Piephoff JV, Michalski JM, Bosch WR, et al. A method to evaluate the impact of daily treatment variation on three-dimensional dose distributions. Int J Radiat Oncol Biol Phys 1992; 27(suppl 1):56.
12. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997; 44:17-22.
13. Kaplan EL, Meier P. Non-parametric estimation and incomplete observations. J Am Stat Assoc 1958; 53:457-481.
14. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35:1-39.
15. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972; 34:187-220.
16. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14:1065-1070.
17. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 1313:452-458.
18. Shaake-Konig C, van den Bogaert W, Dalesio O, et al. Effects of concomintant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326:524-530.
19. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:11-15.
20. Blanke C, Ansari CB, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13:1425-1429.
21. Huber, RM, Schmidt, M, Flentje, M, et al. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB). Proc Am Soc Clin Oncol 2003; 22:622a (Abstract #2501).
22. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22:621 (Abstract #2499).
23. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
24. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer 2000; 89:534-542.
25. van Putten JW, Price A, van der Leest AH, et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003; 9:2472-2477.
26. Lee SW, Choi EK, Lee JS, et al. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 56:996-1004.
27. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002; 54:348-356.
28. Furuse, K, Hosoe, S, Masuda, N, et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy and chemotherapy. Proc Am Soc Clin Oncol 2000; 19:484a (Abstract #1893).
29. Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 51:660-665.
30. Albain, KS, Crowley, JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20:3454.
31. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/ II dose escalation trial. Eur J Cancer 1998; 34:838-844.
32. Koukourakis MI, Giatromanolaki A, Schiza S, et al. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys 1999; 43:107-114.
33. Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIB non-small-cell lung carcinoma. Br J Cancer 1999; 80:1792-1796.
34. Wu H, Bang Y, Choi EK, Ahn YC, et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52:75-80.
35. Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol 2001; 13:110-115.
36. Solomon B, Ball DL, Richardson G, et al. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 2003;4: 353-361.
37. Leong SS, Fong KW, Ong YK, et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer-long term results of a prospective study. Respir Med 2004; 98:1080-1086.
38. Chen LM, Ignacio L, Jacobs R, et al. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III non-small-cell lung cancer. Radiat Oncol Investig 1999; 7:49-53.
39. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001; 19:442-447.
40. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995; 22:70-74.
41. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 16:1860-1870.
42. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial-LUN-46. Semin Oncol 1995; 22:30-33.
43. Novello S, Le Chevalier T. Use of chemo-radiotherapy in locally advanced non-small cell lung cancer. Eur J Cancer 2002; 38:292-299.
44. Antonadou D, Synodinou M, Boufi M, et al. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19:501a (Abstract #1960).
45. Zinner RG, Fossella FV, Komaki R, et al. Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin: a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19:510a (Abstract #1996).
46. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57:875-890.
47. Jeremic B, Shibamoto Y. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer 1995; 13:21-30.
48. Herbert SH, Curran WJ Jr, Rosenthal SA, et al. Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone. Int J Radiat Oncol Biol Phys 1992; 24:37-42.
49. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-1626.
50. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pre-treatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4:1604-1614.
51. Sorensen JB, Badsberg JH, Olsen J, et al. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989; 49:5748-5754.
52. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
53. Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30:1-6.
54. Sculier JP, Paesmens M, Libert P, et al. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. Eur J Cancer 1994; 30A:1342-1347.
55. Fukuoka M, Masuda N, Furuse K, et al. A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991; 9:606-613.
56. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358-364.
57. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation. Int J Radiat Oncol Biol Phys 1999; 45:1143-1149.
58. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423.
59. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991; 20:1183-1190.
60. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997; 39:537-544.
61. Bajard A, Westeel V, Dubiez A, et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004; 45:317-323.
62. Gaspar LE. Brain metastases in lung cancer. Expert Rev Anticancer Ther 2004; 4:259-270.
63. Komaki R, Cox JD, Stark R. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 1983; 9:1467-1470.